1. Home
  2. CRBU vs ARAI Comparison

CRBU vs ARAI Comparison

Compare CRBU & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBU
  • ARAI
  • Stock Information
  • Founded
  • CRBU 2011
  • ARAI 2020
  • Country
  • CRBU United States
  • ARAI United States
  • Employees
  • CRBU N/A
  • ARAI N/A
  • Industry
  • CRBU Medicinal Chemicals and Botanical Products
  • ARAI Diversified Commercial Services
  • Sector
  • CRBU Health Care
  • ARAI Finance
  • Exchange
  • CRBU Nasdaq
  • ARAI Nasdaq
  • Market Cap
  • CRBU 179.7M
  • ARAI 213.7M
  • IPO Year
  • CRBU 2021
  • ARAI N/A
  • Fundamental
  • Price
  • CRBU $2.68
  • ARAI $4.36
  • Analyst Decision
  • CRBU Strong Buy
  • ARAI
  • Analyst Count
  • CRBU 3
  • ARAI 0
  • Target Price
  • CRBU $6.67
  • ARAI N/A
  • AVG Volume (30 Days)
  • CRBU 1.3M
  • ARAI 587.6K
  • Earning Date
  • CRBU 11-05-2025
  • ARAI 08-14-2025
  • Dividend Yield
  • CRBU N/A
  • ARAI N/A
  • EPS Growth
  • CRBU N/A
  • ARAI N/A
  • EPS
  • CRBU N/A
  • ARAI N/A
  • Revenue
  • CRBU $9,121,000.00
  • ARAI $90,725.00
  • Revenue This Year
  • CRBU $8.06
  • ARAI N/A
  • Revenue Next Year
  • CRBU N/A
  • ARAI N/A
  • P/E Ratio
  • CRBU N/A
  • ARAI N/A
  • Revenue Growth
  • CRBU N/A
  • ARAI N/A
  • 52 Week Low
  • CRBU $0.66
  • ARAI $3.03
  • 52 Week High
  • CRBU $3.00
  • ARAI $40.00
  • Technical
  • Relative Strength Index (RSI)
  • CRBU 64.30
  • ARAI N/A
  • Support Level
  • CRBU $2.24
  • ARAI N/A
  • Resistance Level
  • CRBU $2.39
  • ARAI N/A
  • Average True Range (ATR)
  • CRBU 0.19
  • ARAI 0.00
  • MACD
  • CRBU 0.04
  • ARAI 0.00
  • Stochastic Oscillator
  • CRBU 94.75
  • ARAI 0.00

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

About ARAI Arrive AI Inc. Common Stock

Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.

Share on Social Networks: